Corbus today announced that late breaking data from the CRB-913 Canyon-1 Phase 1B study will be presented as a poster presentation at @ObesityWeek 2026, taking place from November 14–17, 2026 in National Harbor, MD. For details: bit.ly/3UGMDtZ $CRBP #ObesityWeek #OW2026

CB1 receptors help regulate appetite, fat storage & metabolism. In #obesity, overactive CB1 signaling drives excess hunger & fat accumulation. CRB-913 is designed to selectively block peripheral CB1 activity without acting on CB1 receptors in the brain. bit.ly/40Lts1n

We believe CRB-913 is positioned as a transformative therapeutic option, potentially reducing the severe health risks associated with #obesity and enabling people to lead healthier, more active lives. Learn about the science behind CRB-913: bit.ly/40Lts1n

TEMPO-1 (n=250) evaluates CRB-701 vs. investigator's choice of capecitabine, cetuximab or docetaxel in 2L+ #OPSCC. FDA approval to proceed was supported by results from Corbus' ongoing Phase 1/2 clinical study of CRB-701, presented at #ASCO26. bit.ly/47ruO4M $CRBP

"For patients with recurrent or metastatic head and neck cancer, there remains a significant unmet need for new treatment options after progression on frontline therapy," said Dr. Cesar A. Perez, TEMPO-1 Principal Investigator. bit.ly/47ruO4M $CRBP #HNSCC #OPSCC

"Dosing the first patient in our TEMPO-1 trial marks an important step in advancing CRB-701 as a potentially novel targeted therapeutic for those impacted by #OPSCC," said Leonardo Nicacio, M.D., Corbus CMO. bit.ly/47ruO4M $CRBP

Corbus today announced the first patient has been dosed in its TEMPO-1 registrational study of CRB-701, a next-generation Nectin-4 targeted ADC, in 2L+ oropharyngeal squamous cell carcinoma. For details: bit.ly/47ruO4M $CRBP #OPSCC #HNSCC

"This initial data seems to indicate that our CB1-targeting drug has comparable weight-loss efficacy to the commercially available oral GLP-1s while delivering a very differentiated GI tolerability profile with markedly less vomiting & nausea." -@CEOCorbus bit.ly/4cHOVPn

ICYMI - Corbus hosted a webcast to discuss positive topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of #obesity. Harold Bays, M.D., an investigator for the study, joined @CEOCorbus to provide insights. Listen to the replay: bit.ly/4yv5nLb

CRB-913 showed rapid, statistically significant weight loss at all doses in CANYON-1, with no plateau observed. All participants who completed the study & received CRB-913 at the 60 mg dose lost weight, with 44.4% losing at least 5% from baseline. bit.ly/46iIA9z $CRBP

Event Reminder: Tune in today, Sept. 14th at 8 a.m. EDT for a conference call featuring @CEOCorbus and Harold Bays, M.D., who will discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Register here: bit.ly/4yv5nLb $CRBP

Corbus announced positive topline data from the CANYON-1 Ph. 1b trial of CRB-913 for obesity. Data showed statistically significant, clinically meaningful weight loss at all 3 doses, with 60 mg achieving mean weight loss of 5% at 12 wks. Read more: bit.ly/46iIA9z $CRBP

Join us tomorrow, September 14th 8:00 a.m. EDT for a conference call to discuss topline data from the CANYON-1 clinical trial and the potential Of CRB-913 In obesity. Register here: bit.ly/4yv5nLb $CRBP

Corbus will host a conference call on Monday, Sept. 14 at 8 a.m. EDT, to discuss topline data for CANYON-1, a Ph. 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker. Details: bit.ly/4cIR0KR $CRBP

Obesity is a global health crisis, doubling in prevalence since 1990 & significantly increasing the risk of heart disease, diabetes, certain cancers, and musculoskeletal disorders. Corbus is developing CRB-913 as a potential treatment option for #obesity. bit.ly/40Lts1n

Early research suggests CRB-913 may amplify the effectiveness of popular diabetes and #obesity treatments like tirzepatide & semaglutide, potentially supporting sustained weight loss without excess muscle loss or neuropsychiatric effects. Learn more: bit.ly/40Lts1n

What is CRB-913? A 2nd-gen oral CB1 inverse agonist designed to act on peripheral CB1 receptors to help reduce food intake and promote weight loss while minimizing CNS side effects. Learn more about the development of CRB-913 for #obesity: bit.ly/40Lts1n

Watch @CEOCorbus' interview with Molecules and Minerals to learn about CRB-913, a next-gen daily oral CB1 inverse agonist for the treatment of #obesity, the CANYON-1 Phase 1b clinical trial and topline data expected in September 2026. bit.ly/4cbfWKI $CRBP

Corbus today provided a corporate update and reported financial results for the 2026 second quarter ended June 30, 2026. For details: bit.ly/3RNjk7J $CRBP

“Despite the remarkable success of GLP-1s and the incretin class, significant treatment gaps exist for people struggling with obesity,” said @CEOCorbus. Learn about Corbus’ CANYON-1 study of CRB-913 for the treatment of obesity: bit.ly/4fLoHfr $CRBP